Ad Header



The Pulse of the Pharmaceutical Industry

FDA approves Roche hemophilia drug Hemlibra

Written by: | | Dated: Thursday, November 16th, 2017


ZURICH (Reuters) – The U.S. Food and Drug Administration on Thursday approved Roche’s Hemlibra for hemophilia suffers, a new medicine the Swiss drugmaker is counting on to help it offset eroding sales of its older medicines that have begun going off patent.

The U.S. regulator approved the drug, also known as ACE910 or emicizumab, as a once-weekly injection for adults and pediatric patients with hemophilia A with factor VIII inhibitors.

The medicine will carry a boxed warning that blood clots were seen in patients who were given rescue treatment to treat bleeds for 24 hours while taking Hemlibra.‍​


Reporting by John Miller


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation